EndoPredict For Personalized Breast Cancer Treatment
Category: Gene & Biotech Services
Exhibitor: GENOMICS BIOSCIENCE AND TECHNOLOGY CO., LTD.
Booth No: M308
EndoPredict is the only test of its kind to combine the established clinical prognostic factors of tumour size and lymph node status with the genetic expression of the
tumor into the ?EPclin Score?. This combination provides valuable additional prognostic information to make an informed treatment decision.
Who can do the EndoPredict testing:
Patient with breast cancer and is luminal A or B type. (ER+/HER2-)
1. Personalized treatment decision
2. Combine clinical prognostic factors and gene fingerprint into the < EPclinScore>
3. Unnecessary chemotherapy can be avoided
4. Identifies risk for early and late recurrence
5. Provides a clear assignment to a low-risk or high-risk group
Products you may be interested in